These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 3171601)

  • 1. The lymphatic route. VI. Distribution of recombinant interferon-alpha 2 in rabbit and pig plasma and lymph.
    Bocci V; Pessina GP; Paulesu L; Nicoletti C
    J Biol Response Mod; 1988 Aug; 7(4):390-400. PubMed ID: 3171601
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The lymphatic route. VII. Distribution of recombinant human interleukin-2 in rabbit plasma and lymph.
    Bocci V; Pessina GP; Nicoletti C; Paulesu L
    J Biol Regul Homeost Agents; 1990; 4(1):25-9. PubMed ID: 2399833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The lymphatic route. V. Distribution of human natural interferon-beta in rabbit plasma and lymph.
    Bocci V; Pessina GP; Paulesu L; Muscettola M; Valeri A
    J Interferon Res; 1988 Oct; 8(5):633-40. PubMed ID: 3235848
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The lymphatic route. IX. Distribution of recombinant interferon-alpha 2 administered subcutaneously with oedematogenic drugs.
    Pessina GP; Bocci V; Carraro F; Naldini A; Paulesu L
    Physiol Res; 1993; 42(4):243-50. PubMed ID: 8280722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plasma and lymph pharmacokinetics of recombinant human interleukin-2 and polyethylene glycol-modified interleukin-2 in pigs.
    Chen SA; Sawchuk RJ; Brundage RC; Horvath C; Mendenhall HV; Gunther RA; Braeckman RA
    J Pharmacol Exp Ther; 2000 Apr; 293(1):248-59. PubMed ID: 10734176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pharmacokinetics of human interferons].
    Furue H; Kobayashi H; Komuro T; Kako M; Mugitani H; Fuse K; Kaise R; Nagai K; Takahashi T; Hirota F
    Gan To Kagaku Ryoho; 1984 Apr; 11(4):935-42. PubMed ID: 6721508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The lymphatic route. 1) Albumin and hyaluronidase modify the normal distribution of interferon in lymph and plasma.
    Bocci V; Muscettola M; Grasso G; Magyar Z; Naldini A; Szabo G
    Experientia; 1986 Apr; 42(4):432-3. PubMed ID: 3956696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The lymphatic route--II. Pharmacokinetics of human recombinant interferon-alpha 2 injected with albumin as a retarder in rabbits.
    Bocci V; Muscettola M; Naldini A; Bianchi E; Segre G
    Gen Pharmacol; 1986; 17(1):93-6. PubMed ID: 3949153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of interferon-alpha-2a on the output of recirculating lymphocytes from single lymph nodes.
    Hein WR; Supersaxo A
    Immunology; 1988 Jul; 64(3):469-74. PubMed ID: 3410492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma levels following intranasal and intravenous administration of human interferon-beta to rabbits.
    Maitani Y; Igawa T; Machida Y; Nagai T
    Drug Des Deliv; 1989 Mar; 4(2):109-19. PubMed ID: 2765103
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.
    Greig NH; Soncrant TT; Wozniak KM; Rapoport SI
    J Pharmacol Exp Ther; 1988 May; 245(2):574-80. PubMed ID: 2835475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal administration of beta-interferon in rabbits.
    Maitani Y; Igawa T; Machida Y; Nagai T
    Drug Des Deliv; 1986 Aug; 1(1):65-70. PubMed ID: 3509321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphatic absorption is the primary contributor to the systemic availability of epoetin Alfa following subcutaneous administration to sheep.
    McLennan DN; Porter CJ; Edwards GA; Martin SW; Heatherington AC; Charman SA
    J Pharmacol Exp Ther; 2005 Apr; 313(1):345-51. PubMed ID: 15579493
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interferons--its method of administration and adverse effect related to pharmacokinetics ].
    Furue H
    Gan To Kagaku Ryoho; 1984 Feb; 11(2):186-93. PubMed ID: 6582804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of routes of administration of interferon in cancer: a review and a proposal.
    Bocci V
    Cancer Drug Deliv; 1984; 1(4):337-51. PubMed ID: 6085757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vasopressin modulation of peritoneal, lymphatic, and plasma drug exposure following intraperitoneal administration.
    Lindnér P; Heath D; Howell S; Naredi P; Hafström L
    Clin Cancer Res; 1996 Feb; 2(2):311-7. PubMed ID: 9816174
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human interferon alpha-2a: delivery to lymphoid tissue by selected modes of application.
    Supersaxo A; Hein W; Gallati H; Steffen H
    Pharm Res; 1988 Aug; 5(8):472-6. PubMed ID: 3244653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pericardial fluid absorption into lymphatic vessels in sheep.
    Boulanger B; Yuan Z; Flessner M; Hay J; Johnston M
    Microvasc Res; 1999 Mar; 57(2):174-86. PubMed ID: 10049665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of human recombinant interferon-beta in monkeys and rabbits.
    Gomi K; Morimoto M; Inoue A; Kobayashi H; Deguchi T; Hara T; Nakamizo N
    Gan; 1984 Mar; 75(3):292-300. PubMed ID: 6724230
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of disappearance from blood and lymphatic delivery of human fibroblast interferon in rat by different administration routes.
    Yoshikawa H; Satoh Y; Naruse N; Takada K; Muranishi S
    J Pharmacobiodyn; 1985 Mar; 8(3):206-10. PubMed ID: 4009412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.